Table 1.

Summary data of key clinical trials of CAR-T cells

Clinical trialPatient groupObjective response rateComplete remission rateOverall survivalReference
ELIANA (Novartis)Children and young adults with relapsed and refractory B-ALL81%81%Median survival 19.1 months11
MSKCCAdults with relapsed B-ALL-83%Median survival 12.9 months12
ZUMA-1 (Kite Pharma)Adults with refractory large B-cell lymphoma82%54%52% at 18 months14
JULIET (Novartis)Adults with relapsed DLBCL or follicular lymphoma64%43% DLBCL 71% follicular lymphomaDLBLC median survival 22.2 months, follicular lymphoma not reached15
CRB-401 (Bluebird bio / Celgene)Relapsed and refractory multiple myeloma89%22%Not available16
  • B-ALL = B-acute lymphoblastic leukaemia; DLBCL = diffuse large B-cell lymphoma